Keytruda 100 MG/4 ML vial 4ML
Ended Awarded Last action
- Contract number
- SPE2DR26FKKD8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $100,474
Award facts
- Contract value 100% obligated
- $100,474.44 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $100,474.44 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Keytruda 100 mg/4 ml vials. This delivery order, issued on November 26, 2025, with an ultimate completion date of December 18, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical procurement for Department of Defense military healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with its IDC under PPV-G GEN V authorized through December 31, 2036, featuring a $499,999,999 ceiling value across a 30-month base period and three optional renewal periods. The company's product portfolio encompasses branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals, including oncology treatments such as Keytruda, which this delivery order specifically addresses. As a long-established federal contractor registered in the System for Award Management since 2001, DMS Pharmaceutical Group leverages its small business status and demonstrated performance across multiple therapeutic categories to support the Department of Defense's medical supply requirements globally.
Quick answers
Who was awarded contract SPE2DR26FKKD8?
SPE2DR26FKKD8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 26, 2025.
How much is contract SPE2DR26FKKD8 worth?
The government has obligated $100,474 on SPE2DR26FKKD8.
Is contract SPE2DR26FKKD8 an order under another contract?
Yes. SPE2DR26FKKD8 is a delivery order under SPE2DR25D9367, an indefinite delivery contract.
Was contract SPE2DR26FKKD8 competed?
The extent of competition for SPE2DR26FKKD8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award